PACIRA BIOSCIENCES, INC. Capital Expenditures Incurred but Not yet Paid
PACIRA BIOSCIENCES, INC. (PCRX) reported Capital Expenditures Incurred but Not yet Paid of $1.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $144.00K, a 78.31% decline year-over-year.
- PACIRA BIOSCIENCES, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $1.36M, a 77.57% increase year-over-year.
- PACIRA BIOSCIENCES, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $352.00K, a 93.17% decline year-over-year.
- PACIRA BIOSCIENCES, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$315.00K.
- PACIRA BIOSCIENCES, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $1.47M, a 73.62% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $5.57M, a 180.78% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $1.98M, a 66.34% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $5.89M, a 13.77% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 9 month as first filed | Capital Expenditures Incurred but Not yet Paid 12 month | Capital Expenditures Incurred but Not yet Paid 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $144.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.51M 10-Q · filed 2026-08-04 | $1.86M derived: sum of 3 quarters · filed 2026-08-04 | $1.54M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $1.36M 10-Q · filed 2026-04-30 | $1.71M derived: sum of 2 quarters · filed 2026-04-30 | $1.40M derived: sum of 3 quarters · filed 2026-04-30 | $2.06M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $352.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $37.00K derived: sum of 2 quarters · filed 2026-02-26 | $701.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.47M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | -$315.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $349.00K derived: sum of 2 quarters · filed 2026-08-04 | $1.12M 10-Q · filed 2025-11-06 | $6.27M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $664.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.43M 10-Q · filed 2026-08-04 | $6.58M derived: sum of 3 quarters · filed 2026-08-04 | $6.39M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $767.00K 10-Q · filed 2026-04-30 | $5.92M derived: sum of 2 quarters · filed 2026-04-30 | $5.73M derived: sum of 3 quarters · filed 2026-04-30 | $5.72M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-12-31 | $5.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.96M derived: sum of 2 quarters · filed 2026-02-26 | $4.96M derived: sum of 3 quarters · filed 2026-02-26 | $5.57M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | -$189.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$192.00K derived: sum of 2 quarters · filed 2025-11-06 | $415.00K 10-Q · filed 2025-11-06 | $927.00K derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $604.00K 10-Q · filed 2025-08-05 | $1.12M derived: sum of 3 quarters · filed 2026-02-26 | $198.00K derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $607.00K 10-Q · filed 2025-05-08 | $1.12M derived: sum of 2 quarters · filed 2026-02-26 | $201.00K derived: sum of 3 quarters · filed 2026-02-26 | $337.00K derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $512.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$406.00K derived: sum of 2 quarters · filed 2026-02-26 | -$270.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.98M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | -$918.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$782.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.47M 10-Q · filed 2024-11-06 | $1.87M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $136.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $2.39M 10-Q · filed 2024-07-30 | $2.79M derived: sum of 3 quarters · filed 2025-02-27 | $5.82M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $2.25M 10-Q · filed 2024-05-07 | $2.65M derived: sum of 2 quarters · filed 2025-02-27 | $5.69M derived: sum of 3 quarters · filed 2025-02-27 | $1.90M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $402.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.43M derived: sum of 2 quarters · filed 2025-02-27 | -$356.00K derived: sum of 3 quarters · filed 2025-02-27 | $5.89M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $3.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$758.00K derived: sum of 2 quarters · filed 2023-11-02 | $5.49M 10-Q · filed 2023-11-02 | $7.59M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-06-30 | -$3.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $2.45M 10-Q · filed 2023-08-02 | $4.56M derived: sum of 3 quarters · filed 2024-02-29 | $1.19M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-03-31 | $6.24M 10-Q · filed 2023-05-03 | $8.35M derived: sum of 2 quarters · filed 2024-02-29 | $4.98M derived: sum of 3 quarters · filed 2024-02-29 | $6.04M derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2021-12-31 | $2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$1.27M derived: sum of 2 quarters · filed 2024-02-29 | -$205.00K derived: sum of 3 quarters · filed 2024-02-29 | $6.83M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | -$3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$2.31M derived: sum of 2 quarters · filed 2022-11-03 | $4.72M 10-Q · filed 2022-11-03 | $4.57M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $8.10M 10-Q · filed 2022-08-03 | $7.94M derived: sum of 3 quarters · filed 2023-02-28 | $15.48M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-03-31 | $7.03M 10-Q · filed 2022-05-04 | $6.88M derived: sum of 2 quarters · filed 2023-02-28 | $14.42M derived: sum of 3 quarters · filed 2023-02-28 | $13.73M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2020-12-31 | -$154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $7.38M derived: sum of 2 quarters · filed 2023-02-28 | $6.69M derived: sum of 3 quarters · filed 2023-02-28 | $9.29M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | $7.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $6.85M derived: sum of 2 quarters · filed 2021-11-03 | $9.44M 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | -$692.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $1.90M 10-Q · filed 2021-08-03 | ||||
| 2020-03-31 | $2.60M 10-Q · filed 2021-05-04 | |||||
| 2019-12-31 | $3.02M 10-K · filed 2022-02-28 | |||||
| 2018-12-31 | $2.89M 10-K · filed 2021-03-01 | |||||
| 2017-03-31 | $1.18M 10-Q · filed 2017-05-04 | $205.00K derived: sum of 2 quarters · filed 2017-05-04 | -$272.00K derived: sum of 3 quarters · filed 2017-05-04 | -$1.16M derived: sum of 4 quarters · filed 2017-05-04 | ||
| 2016-12-31 | -$974.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$1.45M derived: sum of 2 quarters · filed 2017-03-01 | -$2.34M derived: sum of 3 quarters · filed 2017-03-01 | -$789.00K 10-K · filed 2017-03-01 | ||
| 2016-09-30 | -$477.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$1.37M derived: sum of 2 quarters · filed 2016-11-02 | $185.00K 10-Q · filed 2016-11-02 | -$1.02M derived: sum of 4 quarters · filed 2017-05-04 | ||
| 2016-06-30 | -$892.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $662.00K 10-Q · filed 2016-08-04 | -$540.00K derived: sum of 3 quarters · filed 2017-05-04 | -$2.10M derived: sum of 4 quarters · filed 2017-05-04 | ||
| 2016-03-31 | $1.55M 10-Q · filed 2017-05-04 | $352.00K derived: sum of 2 quarters · filed 2017-05-04 | -$1.20M derived: sum of 3 quarters · filed 2017-05-04 | $1.58M derived: sum of 4 quarters · filed 2017-05-04 | ||
| 2015-12-31 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$2.76M derived: sum of 2 quarters · filed 2017-03-01 | $30.00K derived: sum of 3 quarters · filed 2017-03-01 | $1.39M 10-K · filed 2017-03-01 | $418.00K 10-K · filed 2016-02-25 | |
| 2015-09-30 | -$1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $1.23M derived: sum of 2 quarters · filed 2016-11-02 | $2.60M 10-Q · filed 2016-11-02 | $1.66M 10-Q · filed 2015-10-27 | $1.50M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | $2.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $4.15M 10-Q · filed 2016-08-04 | $3.06M derived: sum of 3 quarters · filed 2017-03-01 | |||
| 2015-03-31 | $1.36M 10-Q · filed 2016-05-02 | $268.00K derived: sum of 2 quarters · filed 2017-03-01 | ||||
| 2014-12-31 | -$1.09M 10-K · filed 2017-03-01 | -$1.09M 10-K · filed 2016-02-25 | ||||
| 2014-09-30 | $616.00K 10-Q · filed 2015-10-27 | |||||
| 2013-12-31 | $622.00K 10-K · filed 2016-02-25 | |||||
| 2009-12-31 | $2.25M 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |